CDK1 and metastatic melanoma: In contrast, a recent publication described iASPP as an inhibitor of p53 and a mediator of increased chemoresistance in metastatic melanoma.34 However, these findings do not necessarily contradict our results, since they describe a specific subset of melanoma with sustained iASPP expression and concomitant activation of cyclin B1 and CDK1.